Global disparities in SARS-CoV-2 genomic surveillance
Genomic sequencing provides critical information to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments and vaccines, and guide public health responses. To investigate the spatiotemporal heterogeneity in the global SARS-CoV-2 genomic surveillance, we estimated the impact of sequencing intensity and turnaround times (TAT) on variant detection in 167 countries. Most countries submit genomes >21 days after sample collection, and 77% of low and middle income countries sequenced <0.5% of their cases. We found that sequencing at least 0.5% of the cases, with a TAT <21 days, could be a benchmark for SARS-CoV-2 genomic surveillance efforts. Socioeconomic inequalities substantially impact our ability to quickly detect SARS-CoV-2 variants, and undermine the global pandemic preparedness.
| Errataetall: |
UpdateIn: Nat Commun. 2022 Nov 16;13(1):7003. - PMID 36385137 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 09. Dez. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.11.2023 published: Electronic UpdateIn: Nat Commun. 2022 Nov 16;13(1):7003. - PMID 36385137 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.08.21.21262393 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330055089 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330055089 | ||
| 003 | DE-627 | ||
| 005 | 20231225210453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.08.21.21262393 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1100.xml |
| 035 | |a (DE-627)NLM330055089 | ||
| 035 | |a (NLM)34462754 | ||
| 035 | |a (PII)2021.08.21.21262393 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brito, Anderson F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Global disparities in SARS-CoV-2 genomic surveillance |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Nat Commun. 2022 Nov 16;13(1):7003. - PMID 36385137 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Genomic sequencing provides critical information to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments and vaccines, and guide public health responses. To investigate the spatiotemporal heterogeneity in the global SARS-CoV-2 genomic surveillance, we estimated the impact of sequencing intensity and turnaround times (TAT) on variant detection in 167 countries. Most countries submit genomes >21 days after sample collection, and 77% of low and middle income countries sequenced <0.5% of their cases. We found that sequencing at least 0.5% of the cases, with a TAT <21 days, could be a benchmark for SARS-CoV-2 genomic surveillance efforts. Socioeconomic inequalities substantially impact our ability to quickly detect SARS-CoV-2 variants, and undermine the global pandemic preparedness | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Semenova, Elizaveta |e verfasserin |4 aut | |
| 700 | 1 | |a Dudas, Gytis |e verfasserin |4 aut | |
| 700 | 1 | |a Hassler, Gabriel W |e verfasserin |4 aut | |
| 700 | 1 | |a Kalinich, Chaney C |e verfasserin |4 aut | |
| 700 | 1 | |a Kraemer, Moritz U G |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Joses |e verfasserin |4 aut | |
| 700 | 1 | |a Tegally, Houriiyah |e verfasserin |4 aut | |
| 700 | 1 | |a Githinji, George |e verfasserin |4 aut | |
| 700 | 1 | |a Agoti, Charles N |e verfasserin |4 aut | |
| 700 | 1 | |a Matkin, Lucy E |e verfasserin |4 aut | |
| 700 | 1 | |a Whittaker, Charles |e verfasserin |4 aut | |
| 700 | 0 | |a Danish Covid-19 Genome Consortium |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Impact Project |e verfasserin |4 aut | |
| 700 | 0 | |a Network for Genomic Surveillance in South Africa (NGS-SA) |e verfasserin |4 aut | |
| 700 | 0 | |a GISAID core curation team |e verfasserin |4 aut | |
| 700 | 1 | |a Howden, Benjamin P |e verfasserin |4 aut | |
| 700 | 1 | |a Sintchenko, Vitali |e verfasserin |4 aut | |
| 700 | 1 | |a Zuckerman, Neta S |e verfasserin |4 aut | |
| 700 | 1 | |a Mor, Orna |e verfasserin |4 aut | |
| 700 | 1 | |a Blankenship, Heather M |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Tulio |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Raymond T P |e verfasserin |4 aut | |
| 700 | 1 | |a Siqueira, Marilda Mendonça |e verfasserin |4 aut | |
| 700 | 1 | |a Resende, Paola Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Vasconcelos, Ana Tereza R |e verfasserin |4 aut | |
| 700 | 1 | |a Spilki, Fernando R |e verfasserin |4 aut | |
| 700 | 1 | |a Aguiar, Renato Santana |e verfasserin |4 aut | |
| 700 | 1 | |a Alexiev, Ivailo |e verfasserin |4 aut | |
| 700 | 1 | |a Ivanov, Ivan N |e verfasserin |4 aut | |
| 700 | 1 | |a Philipova, Ivva |e verfasserin |4 aut | |
| 700 | 1 | |a Carrington, Christine V F |e verfasserin |4 aut | |
| 700 | 1 | |a Sahadeo, Nikita S D |e verfasserin |4 aut | |
| 700 | 1 | |a Gurry, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Maurer-Stroh, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Naidoo, Dhamari |e verfasserin |4 aut | |
| 700 | 1 | |a von Eije, Karin J |e verfasserin |4 aut | |
| 700 | 1 | |a Perkins, Mark D |e verfasserin |4 aut | |
| 700 | 1 | |a van Kerkhove, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Sarah C |e verfasserin |4 aut | |
| 700 | 1 | |a Sabino, Ester C |e verfasserin |4 aut | |
| 700 | 1 | |a Pybus, Oliver G |e verfasserin |4 aut | |
| 700 | 1 | |a Dye, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Samir |e verfasserin |4 aut | |
| 700 | 1 | |a Flaxman, Seth |e verfasserin |4 aut | |
| 700 | 1 | |a Suchard, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Grubaugh, Nathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Baele, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Faria, Nuno R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 09. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:09 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.08.21.21262393 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 09 |c 12 | ||